MDV9300

BIOLOGICAL2 trials

Sponsors

Hadassah Medical Organization, Medivation, Inc.

Conditions

DIPGLymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma

Phase 1

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma

Hadassah Medical OrganizationDIPG

Start: 2014-02-28End: 2019-04-30Target: 50Updated: 2016-09-13

Phase 2

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

WithdrawnNCT02653989

Medivation, Inc.Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma, Transformed Indolent Lymphoma

Start: 2016-12-31End: 2018-08-31Updated: 2016-11-25

Related Papers

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Neurological Research and Practice2023-10-198 citations

IT-11 * A PHASE I/ II CLINICAL TRIAL OF CT-011 (PIDILIZUMAB) IN DIFFUSE INTRINSIC PONTINE GLIOMA AND RELAPSED HIGH GRADE GLIOMA: A PRELIMINARY REPORT

Neuro-Oncology2014-11-017 citations